Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652091 · ClinicalTrials.gov registry record
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 146
- Enrollment target
NCT02652091: Completed study, sponsored by Bayer.
NCT02652091 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02652091 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
Interventions
- DRUG Interferon beta-1b (Betaseron, BAY86-5046)
- DEVICE BETACONNECT device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2016-02-05 |
| Est. Completion | 2017-09-13 |
What the finished NCT02652091 record still lists
NCT02652091 is an observational study that tracks outcomes without assigning an intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Interferon beta-1b (Betaseron, BAY86-5046) is the first listed.
NCT02652091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02652091 about?
NCT02652091 is a clinical study titled "Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction". The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
What is the current status of trial NCT02652091?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2016-02-05. Estimated completion is 2017-09-13.
What interventions are being tested in trial NCT02652091?
The interventions under investigation include: Interferon beta-1b (Betaseron, BAY86-5046) (DRUG), BETACONNECT device (DEVICE).
Who is sponsoring clinical trial NCT02652091?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI